Sign in
Taking people in United StatesPhase 4

Tracking Blood Sugar Changes During Treatment for Ketosis-Prone Diabetes

Studies day-to-day blood sugar changes in adults with ketosis-prone diabetes using glucose monitors and insulin.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the 2 sites
Trial code
Registry title
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
Status
Recruiting
Phase
Phase 4
People taking part
12 people, planned
Started
23 Jan 2025
Expected to end
Jan 2027
Type of study
Interventional
Treatments tested
  • Continuous Glucose Monitoring
  • Insulin
Record updated
15 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults of African American ancestry with a BMI of 28 kg/m2 or more who have diabetic ketoacidosis (DKA) from ketosis-prone diabetes, to track blood glucose during treatment toward remission.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Diabetic ketoacidosis (DKA) with plasma glucose > 250 mg/dl (13.9 mmol/L), venous pH < 7.30, serum bicarbonate < 18 mmol/l and serum ketones (beta-hydroxy butyrate) > 1.5 mmol/L. Diabetes diagnosed no more than 90 days before the DKA.

Main reasons for not taking part

  • Significant medical or surgical illness, such as heart problems, chronic kidney or liver problems, or infections
  • Uncontrolled endocrine disorders such as hypercortisolism, acromegaly or hyperthyroidism
  • Anemia, bleeding disorders or abnormal coagulation tests
  • Pregnant
  • Unable to give consent

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Provide informed consent
  • Have a BMI ≥ 28 kg/m2
  • Be of African American ancestry
  • Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose > 250 mg/dl, a venous pH < 7.30, a serum bicarbonate < 18 mmol/l, and serum ketones (beta-hydroxy butyrate) > 1.5 mmol/L

Who cannot take part

  • Diagnosis of diabetes > 90 days before the presentation of DKA
  • Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
  • Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
  • Anemia (hemoglobin < 12.5 g/dL for men, <11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
  • Pregnant
  • Unable to give consent

Where in United States

  • Emory University Hospital MidtownAtlanta, United StatesContact: Priyathama Vellanki, MD, MSTaking people
  • Grady Health SystemAtlanta, United StatesContact: Priyathama Vellanki, MD, MSTaking people

About the trial

What the trial wants to find out

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

The group in the trial

  • Continuous Glucose Monitoring with Adjusted Insulin DosesTreatment being tested

    Patients with ketosis-prone diabetes will wear a continuous glucose monitor (CGM) from the time of hospital discharge until insulin discontinuation. Insulin doses will be adjusted based on CGM glucose readings.

    Treatment: Continuous Glucose Monitoring and Insulin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
Plain-language title
Tracking Blood Sugar Changes During Treatment for Ketosis-Prone DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 June 2026